Evaluation of the interim analysis from the PATRICIA study group: Efficacy of a vaccine against HPV 16 and 18

Expert Review of Anticancer Therapy

Volumn 8, Issue 5, 2008, Pages 701-705

  Frederick, Peter J ^a   Huh, Warner K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cervarix; Cervical cancer vaccine; HPV 16; HPV 18; Human papillomavirus; PATRICIA

Indexed keywords

ALUMINUM HYDROXIDE; HEPATITIS A VACCINE; PHOSPHORYL LIPID A; PLACEBO; VIRUS DNA; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ADAPTIVE IMMUNITY; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS A; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION; INJECTION SITE EDEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; INNATE IMMUNITY; PATIENT COMPLIANCE; PREGNANCY DISORDER; PREGNANCY OUTCOME; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS REPLICATION; ADOLESCENT; ADULT; FEMALE; IMMUNOLOGY; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 45849125397     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.5.701     Document Type: Review

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005).
2. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19 (1999).
3. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind randomised controlled trial. Lancet 369, 2161-2170 (2007).
4. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high grade cervical lesions: a meta-analysis update. Int. J. Cancer. 121, 621-632 (2007).
5. Gissmann L. Human papillomaviruses and genital cancer. Semin. Cancer Biol. 3, 253-261 (1992).
6. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA 89, 12180-12184 (1992).
7. Huh WK, Kendrick JE, Alvarez RD. New advances in vaccine technology and improved cervical cancer prevention. Obstet. Gynecol. 109, 1187-1192 (2007).
8. Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/ aluminum salt combination (AS04) compared to aluminum salt only. Vaccine 24, 5937-5949 (2006).
9. Harro CD, Pang YS, Roden RBS et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl Cancer Inst. 93, 284-292 (2001).
10. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. Lancet 364, 1757-1765 (2004).
11. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006).
12. Clifford GM, Smith JS, Plummer M, Munoz N, N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer 88, 63-73 (2003).
13. Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst. Monogr. 31, 3-13 (2003).
14. Schiffman M, Castle PE, Jeronimo J et al. Human papillomavirus and cervical cancer. Lancet 370, 890-907 (2007).
15. Kinlen LJ, Spriggs AI. Women with positive cervical smears but without surgical intervention: a follow-up study. Lancet 312, 463-465 (1978).
16. Collins Y, Einstein MH, Gosrout BS et al.; Society of Gynecologic Oncologists Education Resource Panel Writing Group. Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol. Oncol. 102, 552-562 (2006).
17. Kahn JA, Burk RD. Papillomavirus vaccines in perspective. Lancet 369, 2135-2137 (2007).
18. Bjorge T, Engeland A, Luostarinen T et al. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective trial. Br. J. Cancer 87, 61-64 (2002).
19. Markowitz LE, Dunne EF, Saraiya M et al. Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm. Rep. 56, 1-24 (2007).
20. Stewart AM. Mandating HPV vaccination - private rights, public good. N. Engl. J. Med. 356, 1998-1909 (2007).
21. Gostin LO, DeAngelis CD. Mandatory HPV vaccination: public health vs private wealth. JAMA. 297, 1921-1923 (2007).
22. Gonik B. Strategies for fostering HPV vaccine acceptance. Infect. Dis. Obstet. Gynecol. 2006(Suppl.) 36797 (2006).
23. Boot HJ, Wallenburg I, de Melker HE et al. Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands. Vaccine 25, 6245-6256 (2007).
24. Delete Y, Meyer C, Reiter S. Universal immunization with human papillomavirus (HPV) vaccine among females aged 12-17 recommended in Germany. Euro. Surveill. 12(4), E070405.2 (2007).
25. McLemore MR. Gardasil: Introducing the new human papillomavirus vaccine. Clin. J. Oncol. Nurs. 10, 559-560 (2006).
26. Agosti JM, Goldie SJ. Introducing HPV vaccines in developing countries - key challenges and issues. N. Engl. J. Med. 356, 1908-1910 (2007).